Inclusion Criteria:

• • Any person ≥18 years of age with diabetes mellitus (except cystic fibrosis- and pregnancy-related) admitted to general (non-ICU) medical-surgical hospital services which require inpatient insulin therapy (i.e.,TID or T2D with ≥2 glucose values ≥180mg/dl)

Exclusion Criteria:

• * Patients admitted to ICU
• * Patients anticipated to require less than 48 hours of admission.
• * Current evidence of hyperglycemic crises (diabetic ketoacidosis or hyperosmolar hyperglycemic state)
• * Severe anemia with hemoglobin \<7 g/dL
• * Evidence of hemodynamic instability
• * Hypoxia (SpO2 \<92% on supplemental oxygen)
• * Pre-admission or inpatient total-daily insulin dose \>150 units daily
• * T2D patients on sliding scale insulin therapy alone (no scheduled basal or bolus insulin) and with glucose levels below 180 mg/dl
• * Patients without diabetes with stress hyperglycemia (not related to steroids or medical nutrition therapy) and with HbA1c \<6.5%
• * Patients on AID as an outpatient
• * Patients who previously participated in AIDING feasibility trial or this RCT
• * Patients with a condition impeding the ability to consent or answer questionnaires
• * Patients who are pregnant or breastfeeding at the time of enrollment
• * Patients who are unable or unwilling to use rapid-acting insulin analogs (Humalog, Admelog, or Novolog) during the study
• * Use of hydroxyurea, high dose of acetaminophen (\>4 grams/day), or high dose ascorbic acid
• * Adults unable to consent
• * Individuals \<18 years of age
• * Pregnant women
• * Prisoners
• * Cognitively impaired or Individuals with Impaired Decision-Making Capacity
• * Individuals who are not able to clearly understand English or Spanish will be excluded